Navigation Links
Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
Date:2/20/2008

nd efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210 phone


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
2. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
3. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
4. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
5. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
6. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
7. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. Keryx Biopharmaceuticals Announces Additions to Management Team
10. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
11. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ... Therapy Market, 2015 - 2025" report to their ... report provides an extensive study on the marketed and ... carried out in this field for over a decade ... in Asian markets; one approved in the EU). There ...
(Date:3/3/2015)... California (PRWEB) March 03, 2015 Crown ... service company, has launched a new Life Science division ... for preclinical research. , The first products released ... isotype controls, and soon to be released in vivo ... will continue to expand their life science portfolio with ...
(Date:3/3/2015)... March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... scientific journal, Expert Opinion on Biological Therapy , ... Zhenggang Zhang , at the Henry Ford Hospital ... Thymosin beta 4 (TB4) has the capacity to promote ... or more post-injury, leading to neurological recovery in each ...
(Date:3/3/2015)... Liberty Corner, New Jersey (PRWEB) March 03, 2015 ... in NJ, has announced today that it has ... DE. Terms of the transaction were not ... engineering consulting services to the energy sector including ... gas, alternative energy, and fossil and nuclear power ...
Breaking Biology Technology:Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Oct. 1 Biomaxx Systems Inc. (Other,OTC: BMXSF), ... our membership,with Bioenergy Australia for 2007. BioMaxx Systems ... in Australia as a result of,our involvement with ... forum established in 1997 to promote renewable,energy solutions. ...
... Boston Scientific,Corporation (NYSE: BSX ) will webcast its ... September 30, 2007 on Friday,October 19, at 8:00 a.m. ... Tobin, President and Chief Executive,Officer, Paul LaViolette, Chief Operating ... Officer. The live webcast and archived replay of ...
... Trubion Pharmaceuticals Inc.,(Nasdaq: TRBN ) ... abstract for TRU-015 for rheumatoid arthritis (RA), ... College of Rheumatology (ACR),Annual Scientific Meeting. This ... Association of Rheumatology Health Professionals (ARHP) Annual,Scientific ...
Cached Biology Technology:Biomaxx Systems Inc. Renews Membership With Bioenergy Australia 2Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results 2Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting 2
(Date:2/24/2015)... NEW YORK , Feb. 24, 2015 This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/13/2015)... 2015 ACT Genomics Co., Ltd., a ... transform cancer genomic information into precision diagnosis and ... raised US$ 8 million in the its first private ... Taipei, Taiwan , ACT Genomics has developed ... aim to implement next generation sequencing (NGS) and ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... In an article published in this month,s issue of ... School of Medicine (BUSM) stress the importance of physicians ... in order to make accurate health assessments for both ... existing regulatory guidelines set a standardized risk assessment of ...
... the Society,s highest honor, the 2013 Wallace H. Coulter ... David Weatherall, MD, of the University of Oxford for ... discoveries, visionary translational research leadership, and a passion for ... care for thousands throughout the developing world. ...
... An international research team led by University of Pittsburgh Cancer ... entering a state of cellular sleep, cancer drugs are more ... ,The findings, which will be published in the August 15 ... available online, are the first to show that it is ...
Cached Biology News:Study finds physicians need to better recognize use of herbal supplements while breastfeeding 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 2Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 3Professor Sir David Weatherall, M.D., recieves 2013 Wallace H. Coulter Award 4UPCI researchers target 'cell sleep' to lower chances of cancer recurrence 2
... instrument can be used as a fully ... Manager Software provides the means to record ... instrument. These data can then be copied ... as Microsoft Excel or Lotus 123, or ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... Oligo Microarray Kit (V2), 2 x ... characterize expression of many thousands of ... during important biological processes. Each microarray ... known ORFs from the S288C strain ...
... an intuitive, easy-to-use operating environment ... data handling, and integration with ... include data acquisition, re-analysis, custom ... both standalone and network environments. ...
Biology Products: